Teleflex (TFX) ArrowADVANTAGE5 PICC Gets FDA 510(k) Clearance for CVP Indication

Article Stock Quotes (1) Comments (0)

Teleflex Inc. (NYSE: TFX), announced its ArrowADVANTAGE5 pressure-injectable peripherally inserted central catheter (PICC) has received FDA 510(k) clearance for central venous pressure (CVP) monitoring indication. CVP measurement in patients is one of the most important assessments in determining cardiovascular function. The change in CVP, correlated with the patient’s clinical status, is a useful indication of adequacy of venous blood volume and alterations in cardiovascular function. CVP also reflects the pumping ability of the right atrium and ventricle.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
• Tesla (TSLA) Announces Partial Model S Recall
• Teleflex to Present at 21st International Congress of the European Association for Endoscopic Surgery (EAES)

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?